"The CPI(M) politburo expresses its deep concern that the life-saving drugs have been taken off the customs duty exemption list. This gazette notification by the government has made these drugs more expensive.
"The CPI(M) demands the government should reconsider this decision," the party said in a statement.
The Left party said the decision will trigger a rise of "at least 22 per cent" in the prices of imported drugs, leading to "severe" economic hardships in case of medicines which have no domestic alternatives.
But within few days, in the face of criticism from various quarters, it had restored exemption on three of the 74 drugs that are mainly used for treatment of hormonal disorders, growth failure and haemophilia.
The government though had defended the move saying the drugs removed from the list can be produced in India and such a move would promote domestic manufacturing in line with its 'Make in India' initiative.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
